| TAH Drug Code | IBNT1 |
|---|---|
| Indications | The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 5 through 11 Years of Age |
| Dosing | IM, 0.2 mL, 5-11 years old, 2-dose series separated by at least 3 weeks |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to the active substance or to any of the excipients. |
| Adverse Effects | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea. |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | IBNT6M |
|---|---|
| Indications | The Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 6 months to 4 Years of Age |
| Dosing | 6 months to 4 years: Primary series, 0.2 mL IM for 2 doses, administered 3 weeks apart, followed by a third dose (0.2 mL) administered at least 8 weeks after the second dose. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to the active substance or to any of the excipients. |
| Adverse Effects | Common Dermatologic: Erythema at injection site, Injection site pain, Swelling at injection site. Musculoskeletal: Arthralgia, Myalgia. Neurologic: Headache. Other: Fatigue, Fever, Shivering. Serious Gastrointestinal: Appendicitis. Immunologic: Anaphylaxis, Hypersensitivity reaction. |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | ICOJN |
|---|---|
| Indications | Indicated for active immunization in children over 6 months, adolescents, and adults to prevent COVID-19. |
| Dosing | Adults and 12 years and older: 0.5 mL IM as a single dose; if previously vaccinated with any COVID-19 vaccine, administer at least 6 months after the last dose of COVID-19 vaccine. 5-11 years: 0.25 mL IM as a single dose; if previously vaccinated with any COVID-19 vaccine, administer at least 6 months after the last dose of COVID-19 vaccine. 6 months through 4 years: (No previous COVID-19 vaccine) 0.25 mL IM for 2 doses administered 28 days apart. (Previously vaccinated with 1 dose of any Moderna COVID-19 vaccine) 0.25 mL IM as a single dose; administer at least 28 days after receipt of previous dose. (Previously vaccinated with 2 dose of any Moderna COVID-19 vaccine or have a known history of SARS-CoV-2 infection) 0.25 mL IM as a single dose; administer at least 6 months after receipt of previous dose. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Known history of severe allergic reactions (eg, anaphylaxis) to any component of the Moderna COVID-19 vaccine (inactive ingredients include tromethamine, acetic acid, sodium acetate, sucrose, cholesterol, distearoylphosphatidylcholine [ie, DSPC], and polyethylene glycol [ie, PEG2000-DMG]) or severe allergic reaction following a previous dose of a Moderna COVID-19 vaccine. |
| Adverse Effects | Common: Erythema at injection site (Adult, 2.1-9% ; adolescent, 9-19.5% ; pediatric, 3.5-18.7%), Injection site pain (Adult, 67.1-89.9% ; adolescent, 90.6-93.1% ; pediatric, 37.4-94.8%), Swelling at injection site (Adult, 2.6-12.7% ; adolescent, 13.3-20.5% ; pediatric, 2.8-17%), Nausea and vomiting (Adult, 5.2-21.4%; adolescent, 11.3-23.9% ; pediatric, 4-24%), Axillary lymphadenopathy, Tenderness (Adult, 5.3-24.8% ; adolescent, 21-27.8% ; pediatric, 4-27.7%), Arthralgia (Adult, 16.4-45.6% ; adolescent, 15-28.9% ; pediatric, 6.2-16.1%), Myalgia (Adult, 19.7-61.7% ; adolescent, 27-46.6% ; pediatric, 9.9-28.2%), Headache (Adult, 24.5-63%; adolescent, 43.4-70.2% ; pediatric, 11.5-54.3%), Fatigue (Adult, 33.3-67.8% ; adolescent, 47.9-67.8% ; pediatric, 32-64.5%), Fever (Adult, 0.3-17.4% ; adolescent, 2.5-12.2% ; pediatric, 3.3-23.9%), Shivering (Adult, 5.3-48.7% ; adolescent, 18.4-43% ; pediatric, 6.4-48%). Serious: Myocarditis, Pericarditis, Facial swelling, Anaphylaxis, Hypersensitivity reaction (0.3-4.3%). |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | ICOJNC |
|---|---|
| Indications | Indicated for active immunization in children over 6 months, adolescents, and adults to prevent COVID-19. |
| Dosing | Adults and 12 years and older: 0.5 mL IM as a single dose; if previously vaccinated with any COVID-19 vaccine, administer at least 6 months after the last dose of COVID-19 vaccine. 5-11 years: 0.25 mL IM as a single dose; if previously vaccinated with any COVID-19 vaccine, administer at least 6 months after the last dose of COVID-19 vaccine. 6 months through 4 years: (No previous COVID-19 vaccine) 0.25 mL IM for 2 doses administered 28 days apart. (Previously vaccinated with 1 dose of any Moderna COVID-19 vaccine) 0.25 mL IM as a single dose; administer at least 28 days after receipt of previous dose. (Previously vaccinated with 2 dose of any Moderna COVID-19 vaccine or have a known history of SARS-CoV-2 infection) 0.25 mL IM as a single dose; administer at least 6 months after receipt of previous dose. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Known history of severe allergic reactions (eg, anaphylaxis) to any component of the Moderna COVID-19 vaccine (inactive ingredients include tromethamine, acetic acid, sodium acetate, sucrose, cholesterol, distearoylphosphatidylcholine [ie, DSPC], and polyethylene glycol [ie, PEG2000-DMG]) or severe allergic reaction following a previous dose of a Moderna COVID-19 vaccine. |
| Adverse Effects | Common: Erythema at injection site (Adult, 2.1-9% ; adolescent, 9-19.5% ; pediatric, 3.5-18.7%), Injection site pain (Adult, 67.1-89.9% ; adolescent, 90.6-93.1% ; pediatric, 37.4-94.8%), Swelling at injection site (Adult, 2.6-12.7% ; adolescent, 13.3-20.5% ; pediatric, 2.8-17%), Nausea and vomiting (Adult, 5.2-21.4%; adolescent, 11.3-23.9% ; pediatric, 4-24%), Axillary lymphadenopathy, Tenderness (Adult, 5.3-24.8% ; adolescent, 21-27.8% ; pediatric, 4-27.7%), Arthralgia (Adult, 16.4-45.6% ; adolescent, 15-28.9% ; pediatric, 6.2-16.1%), Myalgia (Adult, 19.7-61.7% ; adolescent, 27-46.6% ; pediatric, 9.9-28.2%), Headache (Adult, 24.5-63%; adolescent, 43.4-70.2% ; pediatric, 11.5-54.3%), Fatigue (Adult, 33.3-67.8% ; adolescent, 47.9-67.8% ; pediatric, 32-64.5%), Fever (Adult, 0.3-17.4% ; adolescent, 2.5-12.2% ; pediatric, 3.3-23.9%), Shivering (Adult, 5.3-48.7% ; adolescent, 18.4-43% ; pediatric, 6.4-48%). Serious: Myocarditis, Pericarditis, Facial swelling, Anaphylaxis, Hypersensitivity reaction (0.3-4.3%). |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | ICOMDBA1 |
|---|---|
| Indications | Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older. |
| Dosing | IM, 0.5 mL, > or = 18 years, As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine, bivalent Original/Omicron BA.1 which contains elasomeran and an additional mRNA molecule. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine. |
| Adverse Effects | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea. |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | ICOMDBA5 |
|---|---|
| Indications | Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older. |
| Dosing | IM, 0.5 mL, > or = 12 years, As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine, bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule. IM, 0.25 mL, 6-11 years, As booster vaccination. At least 3 months after the second or last booster dose. As a Covid-19 vaccine, bivalent Original/Omicron BA.4/5 which contains elasomeran and an additional mRNA molecule. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | History of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine. |
| Adverse Effects | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea. |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | ICOVBNT |
|---|---|
| Indications | BioNTech COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 12 years of age and older. |
| Dosing | IM, 0.3 mL, > or = 18 years 2 doses administered 3 weeks apart. (Taiwan CDC suggests 2 doses administered 4 weeks apart.) |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Hypersensitivity to the active substance or to any of the excipients. |
| Adverse Effects | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea. |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | ICOVMDN |
|---|---|
| Indications | Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 18 years of age and older. |
| Dosing | IM, 0.5 mL, > or = 18 years 2 doses administered 28 days apart. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine. |
| Adverse Effects | erythema at injection site, pain at injection site, and swelling at injection site. asthenia, fatigue, fever, headache, myalgia, and nausea. |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | ICOXBB15 |
|---|---|
| Indications | For active immunization in children aged 6 months and above, adolescents, and adults to prevent COVID-19 (severe acute respiratory syndrome coronavirus 2 disease). |
| Dosing | For children aged 6 months to 4 years: (1) No prior COVID-19 vaccination and no known SARS-CoV-2 infection history: Two doses, 0.25 mL (25 micrograms) each, at least 28 days apart. (2) Previously received one dose of any Spikevax vaccine: Single 0.25 mL (25 micrograms) dose, at least 28 days after the previous dose. (3) Previously received two doses of Spikevax or had a SARS-CoV-2 infection: Single 0.25 mL (25 micrograms) dose, at least 3 months after the previous dose. For children aged 5 to 11 years: Single 0.25 mL (25 micrograms) dose, with a minimum 3-month interval if previously vaccinated. For adolescents aged 12 and adults: Single 0.5 mL (50 micrograms) dose, with a minimum 3-month interval if previously vaccinated. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Known history of severe allergic reactions (eg, anaphylaxis) to any component of the Moderna COVID-19 vaccine (inactive ingredients include tromethamine, acetic acid, sodium acetate, sucrose, sphingomyelin, cholesterol, distearoylphosphatidylcholine, and polyethylene glycol [ie, PEG2000-DMG]) or severe allergic reaction following a previous dose of a Moderna COVID-19 vaccine. |
| Adverse Effects | Common: Erythema at injection site (Adult, 2.4-9%; adolescent, 13.5-19.5%; pediatric, 3.5-18.7%), Injection site pain (Adult, 73.9-89.9%; adolescent, 92.4-93.1%; pediatric, 37.4-94.8%), Swelling at injection site (Adult, 4.5-12.7%; adolescent, 16.2-20.5%; pediatric, 2.8-17%), Nausea and vomiting (Adult, 5.2-21.4%; adolescent, 11.3-23.9%; pediatric, 6.8-24%), Axillary lymphadenopathy, Tenderness (Adult, 6.1-16.2%; adolescent, 21-23.3%; pediatric, 15.5-18%), Arthralgia (Adult, 16.4-45.6%; adolescent, 15-28.9%; pediatric, 6.2-16.1%), Myalgia (Adults, 19.7-61.7%; adolescents, 26.9-46.6%; pediatrics, 9.9-28.2%), Headache (Adult, 24.5-63%; adolescent, 43.4-70.2%; pediatric, 11.5-54.3%), Fatigue (Adult, 33.3-67.8%; adolescent, 47.9-67.8%; pediatric, 40.1-64.5%), Fever (Adult, 0.3-17.4%; adolescent, 2.5-12.2%; pediatric, 3.3-23.9%), Shivering (Adult, 5.3-48.7%; adolescent, 18.4-43%; pediatric, 6.4-30.3%) Serious: Myocarditis, Pericarditis, Facial swelling, Anaphylaxis, Hypersensitivity reaction (1.5-4.3%) |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |